Monday, 3 November 2014

Efficacy and Safety of Linagliptin in Subjects With Long-Standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-Blind, Placebo-Controlled, Phase III Trials

This pooled analysis found that linagliptin was well tolerated and significantly improved hyperglycemia in a clinically challenging population of patients with long-standing T2DM ... hypothesis that regulation of glucagon release from pancreatic a cells may be of particular relevance for improving hyperglycemia in patients with long-term T2DM (Clinical Therapeutics)

No comments:

Post a Comment